slc-0111
Small moleculeexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2014 (NCT02215850)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Carbonic anhydrase IXINHIBITOR
CA9 inhibitor
- Carbonic anhydrase XIIINHIBITOR
CA12 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
NS(=O)(=O)c1ccc(NC(=O)Nc2ccc(F)cc2)cc1- Mol. weight
- 309.32 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1615281 ↗
Also known as
- slc-0111
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03450018 | Phase 1/Phase 2 (Phase 2) | Jun 30, 2018 | British Columbia Cancer Agency, Canadian Cancer Society, Welichem Biotech Inc. |
| NCT02215850 | Phase 1 | Oct 1, 2014 | Ozmosis Research Inc., Welichem Biotech Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Welichem Biotech Inc. | For profit | 2 | 1 | 2 | 2014 |
| British Columbia Cancer Agency | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Canadian Cancer Society | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Ozmosis Research Inc. | For profit | 1 | 0 | 1 | 2014 |
4 organizations
Page 1 / 1